Immune checkpoint inhibitors (ICIs) have revolutionized the care of patients with cancer. However, median time to response is 2-6 months and many patients derive no benefit from ICIs. Patients are ...
Please provide your email address to receive an email when new articles are posted on . Inpatient immune checkpoint inhibitor use yielded median survival of only 1.5 months. Researchers emphasized the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback